#Taipei #USA #Wound Care #MolecuLight #Debridement

An Innovative Study Validates MolecuLight's Transformative Effect on Wound Care

A recent large and independent randomized controlled trial has substantiated the profound impact of MolecuLight's technology on the debridement of wounds. This breakthrough was highlighted in a study published in the journal Advances in Wound Care, conducted by a team of physicians at Shuang-Ho Hospital in Taipei. It reveals that incorporating MolecuLight's fluorescence imaging devices in surgical protocols for chronic wound care resulted in significantly improved clinical outcomes and reduced healthcare costs.

The trial involved 200 participants and was aptly titled "Application of Real-Time Perioperative Fluorescence Imaging for Achieving High-Quality Debridement: A Randomized Controlled Trial." This meticulously designed study demonstrates that the use of real-time fluorescence imaging allowed for superior surgical debridement quality with dramatically reduced residual bacterial loads.

Key Findings of the Study

1. Faster Healing Times: Patients who underwent debridement guided by MolecuLight devices achieved healing speeds averaging 49 days, compared to 63 days for those receiving standard surgical treatment.
2. Lower Postoperative Infection Rates: The risk of postoperative complications was significantly diminished, displaying an infection rate of only 4% among the MolecuLight group, whereas the control group faced a rate of 22%.
3. Reduced Hospital Stay Duration: Patients treated with MolecuLight devices spent an average of 18 days in the hospital compared to 22 days in the control group.
4. Cost Savings on Antibiotics: Participants in the MolecuLight group required antibiotics for a notably shorter duration, leading to a cost reduction of nearly 40% on antibiotic prescriptions.

Dr. Shun-Cheng Chang, the principal investigator and an associate professor at the Integrated Burn and Wound Center at Shuang-Ho Hospital, stated, "This randomized trial demonstrates that MolecuLight offers measurable and clinically significant benefits in the management of wounds. The ability to visualize bacterial loads in real-time enhances a surgeon's capacity to provide higher-quality debridement and facilitates faster healing, making it an invaluable educational tool for training young physicians in infection control and intraoperative wound assessment."

Wei-Pin Hsieh, CEO of Healtdeva Company Ltd., expressed pride in introducing MolecuLight's advanced imaging technology to healthcare professionals in Taiwan. He noted that this clinical trial reaffirms what many healthcare practitioners have been observing—that real-time fluorescence imaging allows for more precise decision-making, reduced complications, and improved patient outcomes while lessening the overall burden on healthcare systems.

Anil Amlani, CEO of MolecuLight Inc., remarked, "This landmark randomized clinical trial offers the highest level of clinical evidence validating MolecuLight's technology. These results showcase not only the significant clinical benefits such as faster healing, fewer reinfections, and shorter hospital stays, but also the economic value of our imaging system in chronic wound care. We commend the outstanding efforts of the research team at Shuang-Ho Hospital and take pride in seeing MolecuLight elevate global standards of care in wound management and surgical infections."

This clinical trial further cements MolecuLight's crucial role in wound care and perioperative surgical applications worldwide. By enabling the real-time visualization of bacterial presence, this advanced imaging platform provides clinical professionals with crucial information at the point of care, transforming wound management protocols and enhancing patient outcomes.

About MolecuLight Inc.

MolecuLight Inc. is a global private medical imaging company that manufactures and markets the MolecuLight iX® and DX® wound imaging devices. These are the only FDA-approved Class II imaging devices for point-of-care, designed for the real-time detection of elevated bacterial loads in wounds. They also provide accurate digital wound measurements for comprehensive management backed by robust clinical evidence, including over 100 peer-reviewed publications.

About Healtdeva Company Ltd.

Founded in 1992 and based in Taipei, Taiwan, Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmacies. The company focuses on advanced wound care, infection control, and preventive health while collaborating with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through local expertise and strategic channel integration.